Insulin-like growth factors (IGFs) and IGF binding proteins in active Crohn's disease treated with ω-3 or ω-6 fatty acids and corticosteroids

• Published in: Scandinavian journal of gastroenterology 2005-10, Vol.40 (10), p.1214-1221
• Main Authors: Eivindson, Martin, Grønbæk, Henning, Nederby Nielsen, Jens, Frystyk, Jan, Flyvbjerg, Allan, Jørgensen, Lone, Vind, Ida, Munkholm, Pia, Jensen, Søren, Brandslund, Ivan, Hey, Henrik
• Format: Article
• Language: English
• Subjects: Adolescent; Adrenal Cortex Hormones - therapeutic use; Adult; Aged; Biomarkers - blood; Body Mass Index; C-Reactive Protein - metabolism; CDAI score; Crohn Disease - blood; Crohn Disease - drug therapy; Crohn's disease; Endopeptidases - blood; Endopeptidases - drug effects; Fatty Acids, Omega-3 - therapeutic use; Fatty Acids, Omega-6 - therapeutic use; Female; Humans; IGF-I; IGFBP-1; IGFBP-3; IGFBP-3 protease; Immunoassay; inflammatory bowel disease; Insulin - blood; Insulin-Like Growth Factor Binding Proteins - blood; Insulin-Like Growth Factor Binding Proteins - classification; Insulin-Like Growth Factor Binding Proteins - drug effects; Male; Middle Aged; nutrition; Prednisolone - therapeutic use; Somatomedins - classification; Somatomedins - drug effects; Somatomedins - metabolism; Treatment Outcome; ω3-ω6 fatty acids
• ISSN: 0036-5521; 1502-7708
• DOI: 10.1080/00365520510015728

Objective. Catabolism and growth impairment are well-known complications of inflammatory bowel disease (IBD). This may be caused by the disease activity itself and/or the medical treatment, and both may lead to changes in the growth hormone (GH)/insulin-like growth factor I (IGF-I) axis. The aim of the present study was to examine the effects of enteral nutrition, Impact Powder®, as adjuvant therapy to corticosteroid treatment on changes in the GH/IGF-I axis in patients with Crohn's disease (CD). Material and methods. The patients were randomized to 3-IP (ω-3-fatty acid (FA), 3 g/day) or 6-IP (ω-6-FA, 9 g/day). Changes in total IGF-I (tIGF-I) and total IGF-II (tIGF-II), free IGF-I (fIGF-I), IGF binding proteins (IGFBP-1 and IGFBP-3), IGFBP-3 protease activity and insulin levels were examined in 31 patients with active CD (CDAI: 186-603) during treatment with prednisolone (40 mg for 1 week) and tapering the dose by 5 mg/week. Clinical and biochemical markers of inflammation were studied at day 0, and after 5 and 9 weeks. Results. There were no differences at baseline between the two groups. During the treatment period, tIGF-I, fIGF-I and IGFBP-3 increased significantly in both groups compared to baseline (p